Today, there is still no clear and unambiguous view on the role of androgen receptors (AR) in breast cancer, nor in triple-negative breast cancer (TNBC). A series of studies over the years have shown very heterogeneous results. Given the lack of a valid biomarker in TNBC, much hope is placed in the prognos- tic and predictive potential of AR in this aggressive disease. We performed a retrospective cohort study on the consecutive sample of 151 early TNBC patients diagnosed and treated at the University Hospital for Tumors in 2009-2012. We analyzed AR using immunohistochemistry (IHC), with the cutoff value for posi- tivity of ≥1%, referring to current ASCO/CAP recommendations on hormone receptor (ER and PR) analy- sis. The analysis was adjusted for age, comorbidities, menopausal status, histological type of tumor, tumor size, number of positive lymph nodes, stage of disease, Ki-67 proliferation index, type of surgery of the breast and axilla, and treatment with adjuvant chemotherapy and radiotherapy. Correlations of AR with all parameters were calculated, as well as 5 - year disease – free survival (DFS) and overall survival (OS). Incidence of AR (≥1%) in patients with early TNBC in our analysis was 31.1%, of which 85% of patients had AR≥10% and as many as 60% had AR>50%. AR were found to be statistically significantly positively cor- related with age and menopausal status, and statistically significantly negatively correlated with tumor size, grade and Ki67, as well as disease stage. AR≥1% showed no statistically significant association with DFS, median DFS was not reached for both groups of patients, those with AR≥1% as well as those without AR, with HR for disease recurrence or death of 1.08. AR were not statistically significantly associated with OS, there was no difference in the 5-year OS of patients with AR≥1%, compared with those with AR